Table 1. Baseline characteristics of patients with a diagnosis of Lymphoproliferative Disease associated with renal transplantation.
| Case | Gender | Age* | Evolution time† | Etiology of the chronic kidney disease | Induction Therapy | History of rejection /Treatment | Epstein Barr Virus Status‡ | Cytomegalovirus Status** | Creatinine at diagnosis (mg/dL) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Female | 55 | 24 | Tubulo-interstitial nephritis by NSAIDs | None | Yes, steroids, Thymoglobulin | (+) | (+) | 1.62 |
| 2 | Male | 62 | 136 | Unknown | Daclizumab | No | (+) | (+) | 1.05 |
| 3 | Female | 40 | 11 | Focal and segmental glomerulosclerosis | Alemtuzumab | Yes, steroids | (+) | (+) | 1.03 |
| 4 | Male | 50 | 234 | Hypertension | No data | Yes, steroids | No data | No data | 3.62 |
| 5 | Female | 40 | 7 | Diabetes Mellitus 1 | Thymoglobulin | No | (+) | (+) | Loss of graft |
| 6 | Male | 34 | 182 | Alport's disease | None | No | (-) | (+) | 0.94 |
| 7 | Male | 12 | 9 | Posterior Urethra Valves | Thymoglobulin | No | (+) | (+) | 0.7 |
| 8 | Female | 69 | 95 | Hypertension | Alemtuzumab | No | (+) | (+) | 0.67 |
*Age at PTLD diagnosis
† Time in months since the trasplant at PTLD diagnosis;
‡IgG receptor, pre-trasplant;
**IgG receptor, pre-trasplant;